Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence.
about
The impact and effectiveness of pneumococcal vaccination in Scotland for those aged 65 and over during winter 2003/2004Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumoniaModulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide.Vaccination recommendations for the hematology and oncology and post-stem cell transplant populationsAntimicrobial susceptibility and serotype distribution of Streptococcus pneumoniae isolated from patients with community-acquired pneumonia and molecular analysis of multidrug-resistant serotype 19F and 23F strains in Japan.Bacterial pneumonia and pandemic influenza planning.Evolution of vaccination rates after the implementation of a free systematic pneumococcal vaccination in Catalonian older adults: 4-years follow-upIdentification of a human immunodominant B-cell epitope within the immunoglobulin A1 protease of Streptococcus pneumoniae.Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodiesDiversity of pneumococcal surface protein A (PspA) among prevalent clones in SpainPneumococcal serotypes and mortality following invasive pneumococcal disease: a population-based cohort studyRationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke.Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or olderImpact of human immunodeficiency virus infection on Streptococcus pneumoniae colonization and seroepidemiology among Zambian womenEfficacy of pneumococcal vaccination in adults: a meta-analysis.Serotype distribution in non-bacteremic pneumococcal pneumonia: association with disease severity and implications for pneumococcal conjugate vaccinesPneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.Active Immunization with Pneumolysin versus 23-Valent Polysaccharide Vaccine for Streptococcus pneumoniae KeratitisPneumococcal immunization in older adults: implications for the long-term-care setting.Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines.Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trialPotential cost-effectiveness and benefit-cost ratios of adult pneumococcal vaccination in GermanyIncreasing hospital admissions for pneumonia, EnglandVaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomes.A live-attenuated pneumococcal vaccine elicits CD4+ T-cell dependent class switching and provides serotype independent protection against acute otitis media.Pneumococcal polysaccharide vaccine: cost-effectiveness recommendations in adults.Pneumococcal vaccination among adults with chronic respiratory diseases: a historical overview.Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.Discrepant serological assays for Pneumococcus in renal transplant recipients - a prospective study.Vaccine profile of PPV23: Beijing Minhai Biotech 23-valent pneumococcal vaccine.Polysaccharide pneumococcal vaccination: new evidence.Epidemiological and molecular characteristics of a highly lethal pneumococcal meningitis epidemic in Burkina Faso.Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in the general population aged ≥ 60 years: 3 years of follow-up in the CAPAMIS study.Effectiveness of a 23-valent polysaccharide vaccine in preventing pneumonia and non-invasive pneumococcal infection in elderly people: a large-scale retrospective cohort study.Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).Involvement of Zizimin2/3 in the age-related defect of peritoneal B-1a cells as a source of anti-bacterial IgM.
P2860
Q21261529-A6FE3952-A874-44E8-ACAD-744DF6DB722DQ23911823-214C1C90-343F-49B7-B43F-6C2F19B9FCCCQ24532019-3E546304-7138-46D9-AFAF-BA66F7002E6FQ26829398-921DCF6C-328E-454C-AF93-9E6411D27928Q30354131-37A304A9-7A64-4370-8170-0BA7BE0F4B24Q30371215-E18B31E3-C75B-404C-BC31-8D1231C9700CQ33257893-2658EF4A-88F6-4AFC-A899-420769069037Q33311002-02A8122B-4735-4557-8537-5FD4E66BCBBBQ33312893-58E4523D-2023-4392-AFD2-9EE33D724DBFQ33439975-DE1573E9-9C2C-4FCD-9967-9A35BC8FC260Q33452537-2C0FEC6C-3741-4934-9649-2A3B7442C804Q33525198-D175282B-209D-4573-8D01-FD7B5627BC6BQ33542866-E30DD6A3-EEE0-4AEB-955A-8D684EE41EBEQ34590674-E157B105-5F01-41EC-BCFF-F48FE5859152Q34657877-AC0D9A5E-9D97-44D3-9F49-F4AB81DC6250Q34979620-6EE01C2E-1EB4-4323-9583-1E060CC7938EQ35783722-312E218A-2B7C-4279-8A27-FFE8F1787212Q35826641-078F46C5-3B7A-4327-AB91-5E09EE366666Q35964591-3C73B849-9674-4216-B374-BFA5FE5FEC2EQ36156085-8D41B798-5EED-4B8B-A9E4-B59CD77D52ABQ36255735-FB5490FC-EDB3-461C-9766-F97FE581486EQ36295092-2062D75D-CD71-4C1E-8021-A190C378F228Q37009138-41549776-6B33-4C8A-9868-499DDC278D8FQ37197138-CA933543-1505-4932-9218-F635A24A9A95Q37606439-4E198EE6-FA86-49A0-858F-6CEAD675A289Q37609401-86F96413-16CC-4788-AF13-4733094CC744Q37981768-F3EDF7BC-DEDF-4C69-9581-B77944274701Q38082673-4EFBA58B-513D-4A60-B428-B3E044E081A7Q38560859-E53B7430-8A23-4AFD-9354-00ABD2C7F098Q38739122-64111EFA-A444-4EE4-851A-3B93BF24739AQ40522492-90038B24-230D-48FF-BB57-9718B5C98ED2Q42721720-81BA276F-F184-471A-8A30-C708793F569AQ43933092-2F9332E1-2CDC-490D-8212-198254D24FBDQ44532649-1EB65373-AB5B-48EF-93D0-DF3AC207C776Q47711077-6C46D0F5-708B-45BA-B6B2-0F919170D153Q50090256-37383E25-51BA-4FFA-B17E-6FF3B2BA7589Q51787020-A27D8C54-E46D-4500-8B6A-B1756617489C
P2860
Efficacy of polysaccharide pneumococcal vaccine in adults in more developed countries: the state of the evidence.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Efficacy of polysaccharide pne ...... es: the state of the evidence.
@ast
Efficacy of polysaccharide pne ...... es: the state of the evidence.
@en
type
label
Efficacy of polysaccharide pne ...... es: the state of the evidence.
@ast
Efficacy of polysaccharide pne ...... es: the state of the evidence.
@en
prefLabel
Efficacy of polysaccharide pne ...... es: the state of the evidence.
@ast
Efficacy of polysaccharide pne ...... es: the state of the evidence.
@en
P2093
P1476
Efficacy of polysaccharide pne ...... es: the state of the evidence.
@en
P2093
Andrew J Hall
Felicity Cutts
Punam Mangtani
P356
10.1016/S1473-3099(03)00514-0
P577
2003-02-01T00:00:00Z